Cordyceps Sunshine Biotech Holdings Co., Ltd. (RAJAF)
OTCMKTS · Delayed Price · Currency is USD
8.56
+1.06 (14.13%)
At close: May 22, 2025

RAJAF Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Revenue
1.250.880.05-0.2
Revenue Growth (YoY)
42.03%1555.66%---
Cost of Revenue
0.720.120.01-0.06
Gross Profit
0.530.770.04-0.14
Selling, General & Admin
0.720.540.340.090.13
Research & Development
--0.120.03-
Other Operating Expenses
----0
Operating Expenses
0.720.540.450.120.13
Operating Income
-0.180.23-0.42-0.120.01
Interest Expense
-0.02-0.04---0.03
Interest & Investment Income
--000
Other Non Operating Income (Expenses)
0.010--0
EBT Excluding Unusual Items
-0.20.19-0.42-0.12-0.02
Gain (Loss) on Sale of Assets
0----
Pretax Income
-0.190.19-0.42-0.12-0.02
Income Tax Expense
0.030.02--0
Earnings From Continuing Operations
-0.230.17-0.42-0.12-0.02
Earnings From Discontinued Operations
-0.58-0.3-0.37-
Net Income
-0.230.75-0.72-0.49-0.02
Net Income to Common
-0.230.75-0.72-0.49-0.02
Shares Outstanding (Basic)
111111104100100
Shares Outstanding (Diluted)
111111104100100
Shares Change (YoY)
-6.42%4.42%--
EPS (Basic)
-0.000.01-0.01-0.00-
EPS (Diluted)
-0.000.01-0.01-0.00-
Free Cash Flow
-0.040.04-0.32-0.47-1.86
Free Cash Flow Per Share
---0.00-0.01-0.02
Gross Margin
42.58%86.84%74.21%-69.83%
Operating Margin
-14.67%25.82%-778.78%-6.48%
Profit Margin
-18.05%85.17%-1350.92%--10.00%
Free Cash Flow Margin
-2.97%4.56%-602.91%--922.13%
EBITDA
0.240.28-0.390.030.05
EBITDA Margin
19.16%32.25%--26.25%
D&A For EBITDA
0.420.060.020.150.04
EBIT
-0.180.23-0.42-0.120.01
EBIT Margin
-14.67%25.82%--6.48%
Effective Tax Rate
-11.28%---
Revenue as Reported
1.250.880.05-0.2
Source: S&P Global Market Intelligence. Standard template. Financial Sources.